Experimental CAR-T shot targets Hard-to-Treat prostate cancer
NCT ID NCT07240857
First seen Nov 21, 2025 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This early-phase study tests a new treatment called ACT#001 for men with castration-resistant prostate cancer that has not responded to other therapies. The treatment involves injecting specially engineered immune cells (CAR-T cells) directly into the tumor. The main goal is to check safety, and researchers will also measure if PSA levels drop by at least half. The study plans to enroll 18 adults who are still on hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.